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We just heard and read an eloquent presentation from Stiles
and associates1 from New York Hospital. The basic import
of their study is that when positron emission tomography
(PET) using fluorodeoxyglucose (FDG) scan predicts that
a patient has stage IA non–small cell lung cancer (NSCLC),
the patient truly has pathologic stage IA disease only 65% of
the time. There are a few concerns about the methodology of
this well done study: not all patients received integrated pos-
itron emission tomography/computed tomography (PET/
CT), which has been shown to be superior in several studies
and two prospective studies when compared to dedicated
PET.2-4 The time interval between the PET scan and the
eventual operation is not specified. However, their findings
are accurate, honest, and important. Moreover, the results
of their study are very similar to a previous study from our
group, which was presented at a meeting of The Society of
Thoracic Surgeons and published in 2005.5 The real ques-
tion that should be posed is not about the validity of this
study’s findings but rather about its clinical significance.
In this point–counterpoint article, I will focus on the specific
results of the article by Stiles and associates1 and repeatedly
query how the inaccuracy of PET injured patient care. How
many patients had their treatment or care misguided by the
PET’s incorrect prediction? Inasmuch as these patients un-
derwent anatomic pulmonary resection and complete tho-
racic lymphadenectomy, the answer is few to none. The
same question must then be asked if the patient had under-
gone a less invasive procedure, which may be more com-
monly chosen in the future.
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FINDINGS—MISCALCULATION OF THE T
STATUS
Stiles and colleagues1 found that PET was correct in pre-
dicting the T status as T1 in 192 of the 266 (72%) patients
and incorrect in the remaining 28%. Interestingly, in our
study, my colleagues and I5 found the T status to be incorrect
in 47% of patients who underwent FDG-PET. Table 1
depicts these inconsistencies and also shows the clinical
impact that the incorrect PET prediction had on patient
care in the patients in Stiles and associates’ study. In 52
(20%) patients, the stage of disease was T2 as a result of vis-
ceral pleural invasion, and in 20 (7.5%) patients, the disease
stage was T4 as a result of satellite nodules. Two patients had
T3 disease. Inasmuch as the preoperative and intraoperative
therapy of all these patients would not have changed had the
true pathologic T status been known before surgery, no
patient received the improper therapy. The main reason
this is true centers on the fact that the authors performed
the correct operation: anatomic pulmonary resection with
complete thoracic lymphadenectomy. However, could this
statement be made if patients had undergone some of our
new minimally invasive techniques that more and more pa-
tients are asking us to consider, for example, stereotactic
radiotherapy or radiofrequency ablation or even video-
assisted wedge resection? The answer is possibly no, espe-
cially for the first two therapies. Next, let us consider the
misstaging that occurred with the nodal (N) status.
MISCALCULATION OF THE N AND M STATUS
In their article, Stiles and colleagues1 found that the nodal
or N status was wrong in 21 (12%) patients and correct in
82% of the patients. Review of their results shows that 16
(7%) patients had unsuspected N1 disease and 5% had
unsuspected N2 disease. In our prospective misstaging
study, we5 reported a 9%, or almost double, incidence of
unsuspected N2 disease compared with the authors’ study.
Again, we need to consider how the PET’s misstaging hurt
patient care. Inasmuch as the treatment of N1 or stage II
disease is resection followed by adjuvant therapy, the 16
patients who had unsuspected N1 disease received no ad-
verse therapy because of the PET’s inaccuracy. Their care
was the same, surgery followed by adjuvant therapy, as if
their N1 status had been correctly identified preoperatively.
This fact again is only true since Stiles and colleagues per-
formed lobectomy in the vast majority of these patients
and removed all of the regional N1 lymph nodes. Could
the same statement be made if patients had undergoneery c January 2009
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stereotactic radiation, or radiofrequency ablation or even
wedge resection? The answer is no.
Now we are left with only 13 (5%) patients who had
unsuspected N2 disease and 2 (0.8%) who had unsuspected
M1 disease from the same histologic cancer in another lobe.
Recall that we started with 266 in the study and 97 were
incorrectly staged. We have already shown that all but these
15 would have received the same care even if the PET had
correctly staged the disease. Now let’s consider the 13 pa-
tients with unsuspected (missed by PET) N2 disease.
Perhaps these are the patients that one could argue had their
care compromised because of the inaccuracies of the PET
scan. This charge is easy to levy because many consider
the best treatment of N2 disease to be preoperative chemo-
radiotherapy followed by careful restaging and surgical
resection in properly selected patients.6 However, despite
this claim, the truth is there are no data that show that
patients with unsuspected or microscopic (PET negative
N2 disease) disease fare better if given neoadjuvant therapy
followed by resection, compared with resection followed by
adjuvant therapy. Thus, once again it appears that patient
care or therapy may not have been hurt because of PET’s
inaccuracies. Finally, we are left with only 2 (0.8%) patients
who had M1 disease from nodules palpated in the other
lobes. As Bryant7 and I showed in 2008, if thoracotomy is
used and the lobes that are not imaged to have nodules or
masses in them are carefully palpated (which is difficult to
do with video-assisted thoracic surgery), it is not uncommon
to identify nonimaged nodules, some of which will be malig-
nant. Although the clinical significance of these nodules is
unknown, and thoracotomy with careful palpation of the
lung tissue that is not planned to be resected, and then ana-
tomic pulmonary resection of the cancer with complete tho-
racic lymphadenectomy is performed, patient care remains
uncompromised. However, if lesser procedures are used,
the patient may be left with unresected cancer and the preop-
erative misstaging is more likely to become clinically signif-
icant. Finally, some may argue that these lesser procedures
may not hurt patient care because these other malignant areas
(nodes or nodules) will grow and be discovered on postoper-
ative surveillance at 3 or 6 months. Even if this claim is true,
which is dubious, the patient has still lost the benefit of adju-
vant therapy at the time of the initial treatment because his or
her stage was not correctly identified. Moreover, the patient
has to go through the added anxiety of another operationThe Journal of Thoracic andand staging tests and the added cost of the procedure and its
inherent morbidity. Thus, Stiles and coworkers’ article, which
highlights the understating of PET, shows that when intrao-
perative resection with lung palpation and complete thoracic
lymphadenectomy is performed, the misstaging of PET does
not seem to negatively affect patient care. However, what
about the overstaging of PET?
PROBLEM OF PET OVERSTAGING DISEASE
Most critics would say that the real problem with PET
comes with overstaging (false positives). The truth is that
this is a problem only when physicians use poor judgment
and treat patients using PET because ‘‘it lit up hot on
PET’’ instead of performing careful tissue biopsy. We and
others have shown that PET only provides targets and that
biopsy specimens of these targets need to be obtained; there-
fore, the problem with overstaging does not lead to incorrect
care. However, theoretically it could lead to unnecessary
tests and procedures (ie, bone scan for false positive bone
on PET, mediastinoscopy, endobronchial ultrasound, or
endoscopic ultrasound/fine-needle aspiration for false posi-
tives lymph nodes). All these tests can be expensive, and
there is morbidity with any procedure. The truth is that
many surgeons perform mediastinoscopy routinely on all
patients; if so, then the PET’s misstaging again has not led
to a change in patient care or any added cost.
Next, the critic might argue that PET scans light up the
bone falsely or the liver falsely; therefore, bone scans are
ordered unnecessarily, and tests to rule out adrenal metastasis
are ordered aswell. However, a large number of surgeons and
physicians do bone scans routinely irrespective of the PET
findings, and most CT scans cut down through the upper
abdomen, allowing views of the liver and the adrenal glands
in patients with a lung nodule. The truth again is that the ex-
pense added by PET scan is probably minor, even when it is
falsely positive. Again, patient care is not compromised. Fi-
nally, somemay argue that one should perform amediastino-
scopy, endobronchial ultrasound, and endoscopic ultrasound
TABLE 1. Review of data showing the lack of clinical impact on PET’s
misstaging in patients assumed to have stage IA NSCLC
No. of
patients
Types of misstaging
error by PET
Impact on patient
care before surgery
T status
52 T2 not T1 None
20 T3 not T1 None
20 T4 not T1 None
N status
18 N1 instead of N0 None
13 N2 instead of N0 None
M status 2 M1 (same type of
malignant nodule
in other lobe)
instead of N0
None
PET, Positron emission tomography; NSCLC, non–small cell lung cancer.Cardiovascular Surgery c Volume 137, Number 1 21
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N2 disease as described above. The clinical significance of
this microscopic disease from the preoperative care of pa-
tients remains to be ascertained. Thus, we are now left with
the question, ‘‘Then why do a PET at all?’’
ADVANTAGES OF PET SCAN
If PET is inaccurate for patients thought to be in stage IA,
and up to 30% are not, then why perform PET at all? There
are many reasons, as shown by prospective studies. First,
PET provides the best staging to rule out metastatic M1 dis-
ease.8 This leads to better patient selection and avoids thora-
cotomy and pulmonary resection that probably is not
helpful. Second, PET is the best staging tool of the medias-
tinum, as shown by a multitude of studies.9-11 Third, it is the
only test that provides the maximum standardized uptake
value of the primary tumor. We and others have shown the
importance of this in terms of surveillance, biologic aggres-
siveness, and perhaps the use of adjuvant chemotherapy.
Moreover, its role for restaging after neoadjuvant chemora-
diotherapy is critical.6 The percent change in the maximum
standardized uptake value is the best tool to help guide
patient therapy as well as monitor the response rate to treat-
ments given.When neoadjuvant therapy is given, the change
in the maximum standardized uptake value of both the pri-
mary tumor and the mediastinal lymph nodes is the best
predictor of pathology. Therefore, although PET may be
imperfect, it like all other tests has false negative results
(as shown by Stiles and colleagues1) and false positive
results. However, when physicians who are critical thinkers
and experts in lung cancer interpret PET and then provide
the appropriate care as guided by the PET findings, these
misstaging errors rarely hurt patient care.
Although Stiles and colleagues1 have presented important
data on the shortcomings of PET, as my colleagues and I5
did in 2005, the truth is that PET should remain a mandatory
part of the preoperative evaluation of a patient with appar-
ently resectable NSCLC. It remains the standard of care
for these patients. If physicians would obtain biopsy tissue
of all targets suggested by integrated PET/CT as well as
by contrasted 5-mm cut CT scans instead of assuming cancer22 The Journal of Thoracic and Cardiovascular Surin the abnormal lesion, the stage, care, and survival of pa-
tients with NSCLCwould be improved. Finally, and perhaps
most important, if patients undergo pulmonary resection
(with careful bimanual lung palpitation) along with com-
plete thoracic lymphadenectomy, they receive outstanding
care that maximizes their survival. However, if patients
and physicians elect for lesser procedures, such as stereotac-
tic radiation or radiofrequency ablation that does not remove
all of the mediastinal lymph nodes, then patient care and sur-
vival are bound to suffer. The well-documented misstagings
by PET, in particular false negative results, have to be con-
sidered if patients elect to undergo nondefinitive therapy.
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